Barclays Reiterates Overweight Rating on Spring Works Therapeutics (SWTX)
Tweet
Share
E-mailGet Alerts SWTX Hot Sheet
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Barclays analyst Peter Lawson reiterated an Overweight rating and $63.00 price target on Spring Works Therapeutics (NASDAQ: SWTX).
The analyst commented, "SpringWorks completed the rolling NDA submission for mirdametinib (MEK inhibitor) in NF1-PN - in line with recent management guidance - see details below from our recent NDR with SpringWorks. We would expect priority review, which could put a potential FDA approval sometime in early 2025."
For an analyst ratings summary and ratings history on Spring Works Therapeutics click here. For more ratings news on Spring Works Therapeutics click here.
Shares of Spring Works Therapeutics closed at $38.53 yesterday.
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays, Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
